Rivercell
Rivercell builds experimental data infrastructure and AI models to predict how human cells respond to treatments.
$25MSeed
ParticipantA
Alven
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
Alven is an investment firm whose own news covers Archy’s Series C and which Attention identifies as a returning investor.
Recorded funding activity
Archy combines dental-practice operations and clinical software with AI tools for routine administrative work. Attention develops agents for revenue-team workflows. The recorded history also includes Generare, which produces molecular data for drug development. These company-level events connect Alven’s attribution across distinct business applications.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $85.7M 3 disclosed · full round size, not this investor’s share